Similar Products:
| Image | Product | Manufacturer / Marketed By | Price |
|---|---|---|---|
 | LuciAfa 40 mg Tablet | Lucius Pharma | Ask for Price |
Xovoltib 40 mg Tablets are manufactured by Boehringer Ingelheim India pvt ltd in Germany and contain 40 mg of Afatinib per tablet. Each Blister pack includes 28 tablets per bottle, making Xovoltib 40 mg Tablets an effective option for Lung Cancer . Prescription Required from your healthcare provider to purchase Afatinib medicine. Indogenmed deals in all type of generic Afatinib medicine.
Targets EGFR signaling pathways involved in cancer cell growth
Precision oncology therapy guided by genetic mutation testing
Oral targeted treatment suitable for outpatient use
May help slow disease progression in certain patients with EGFR-mutated NSCLC
Part of modern targeted therapy strategies for lung cancer
Xovoltib (afatinib) may be prescribed for:
Metastatic non-small cell lung cancer (NSCLC) with EGFR mutation
Patients with tumors confirmed to have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations
First-line treatment of EGFR mutation–positive advanced lung cancer
Treatment decisions are based on molecular diagnostic testing and clinical evaluation.
Afatinib works by inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and other members of the ErbB receptor family. These receptors regulate signaling pathways that control cell growth, division, and survival.
In certain lung cancers, mutations in the EGFR gene cause these pathways to remain continuously active, leading to uncontrolled tumor growth. Afatinib blocks these receptors and disrupts abnormal signaling, which may help reduce cancer cell proliferation and slow disease progression when used as prescribed and monitored by an oncology specialist.
Xovoltib tablets are taken orally once daily, unless directed otherwise by a healthcare professional.
Tablets should be taken on an empty stomach (at least 1 hour before or 2 hours after meals).
Tablets should be swallowed whole with water.
Dose adjustments may be required depending on treatment tolerance and side effects.
Treatment duration is determined by the oncologist based on response and clinical condition.
Common side effects
Diarrhea
Skin rash or acne-like rash
Mouth sores (stomatitis)
Dry skin
Decreased appetite
Nail infections or nail changes
Serious side effects
Severe diarrhea and dehydration
Lung inflammation (interstitial lung disease)
Liver function abnormalities
Severe skin reactions
Eye problems such as keratitis
Patients should contact their healthcare provider if severe symptoms occur.
Risk of severe diarrhea, which may lead to dehydration
Possible interstitial lung disease (lung inflammation)
Liver function abnormalities may occur
Skin reactions and photosensitivity
Eye disorders such as keratitis
Inform healthcare providers about all medications and supplements being used
Pregnancy should be avoided during treatment
Take the medicine exactly as prescribed by your oncologist
Attend scheduled medical monitoring and laboratory tests
Report symptoms such as severe diarrhea, breathing difficulty, or skin reactions
Maintain proper hydration during treatment
Inform your doctor about all medications and supplements you take
Do not stop treatment without consulting your healthcare provider
Afatinib has been evaluated in multiple clinical trials for patients with EGFR mutation–positive non-small cell lung cancer. The LUX-Lung clinical trials demonstrated improved progression-free survival in certain patients compared with earlier therapies. Based on these results, afatinib received approvals from regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific lung cancer indications.
U.S. Food and Drug Administration (FDA) – Afatinib Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201292s019lbl.pdf
European Medicines Agency (EMA) – Afatinib Product Information
https://www.ema.europa.eu
National Cancer Institute – Afatinib Drug Information
https://www.cancer.gov
Drugs.com – Afatinib Drug Information
https://www.drugs.com
ClinicalTrials.gov – Afatinib Clinical Studies
https://clinicaltrials.gov
Related Products
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade
READ MORE »Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.